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Background: The limited within-breed genetic heterogeneity and an enrichment of disease-predisposing alleles
have made the dog a very suitable model for the identification of genes associated with risk for specific diseases.
Canine mammary cancer is an example of such a disease. However, the underlying inherited risk factors for canine
mammary tumours (CMTs) are still largely unknown. In this study, 52 single nucleotide polymorphisms (SNPs) in ten
human cancer-associated genes were genotyped in two different datasets in order to identify genes/alleles
associated with the development of CMTs. The first dataset consisted of English Springer Spaniel (ESS) CMT cases
and controls. ESS is a dog breed known to be at increased risk of developing CMTs. In the second dataset, dogs
from breeds known to have a high frequency of CMTs were compared to dogs from breeds with a lower
occurrence of these tumours.
Results: We found significant associations to CMT for SNPs and haplotypes in the estrogen receptor 1 (ESR1) gene in
the ESS material (best PBonf = 0.021). A large number of SNPs, among them several SNPs in ESR1, showed significantly
different allele frequencies between the high and low risk breed groups (best PBonf = 8.8E-32, best PBPerm = 0.076).
Conclusions: The identification of CMT-associated SNPs in ESR1 in two independent datasets suggests that this gene
might be involved in CMT development. These findings also support that CMT may serve as a good model for human
breast cancer research.
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The modern dog breeds are a result of vigorous line-
breeding and often originate from a few founding ances-
tors. This has led to extreme phenotypic variation between
breeds, but limited genetic variation within breeds [1].
Some breeds have a considerably higher susceptibility to
certain diseases than others. This indicates an enrichment
of risk alleles within these specific breeds. Canine cancer is
an example of such a disease. Mammary tumours are
among the most common canine cancer forms [2]. Elderly,
intact bitches are primarily affected by these tumours [3,4],
with a higher incidence in breeds such as the English
Springer Spaniel, Boxer, Cocker Spaniel and Dachshund* Correspondence: KajaSverdrup.Borge@nvh.no
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reproduction in any medium, provided the or[3-8]. The differences in breed predisposition clearly indi-
cate a genetic influence on canine mammary tumour
(CMT) development. There are many similarities between
CMTs and human breast cancer. Among the shared dis-
ease characteristics are a spontaneous occurrence of tu-
mours, by which females are primarily affected, and a
hormonal influence on tumour development (e.g.
oestrogen and progesterone) (as reviewed by Queiroga
et al. 2011 [9]). Regional lymph node metastasis seems to
be less important as a prognostic factor in dogs than in
humans, but metastatic spread is otherwise broadly equal
[10]. There are also similarities regarding the histological
features and classifications of human breast cancer and
CMTs. But while epithelial tumours are by far the most
common in humans, CMTs relatively frequently also con-
tain myoepithelial and mesenchymal components. Fur-
thermore studies indicate that CMT and human breast
cancer have several mutual prognostic markers andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Borge et al. BMC Veterinary Research 2013, 9:69 Page 2 of 9
http://www.biomedcentral.com/1746-6148/9/69genetic risk factors for disease (as reviewed by Queiroga
et al. 2011 [9]). Still, the underlying inherited risk factors
for CMTs are largely unknown. Previous studies of ge-
notypes, gene and protein expression in CMTs have
identified possible candidate genes and pathways, but
the results need to be confirmed or are somewhat in-
consistent. However, a study on BRCA1 and BRCA2,
two genes well-known to be involved in human breast
cancer, showed associations of these genes with mam-
mary tumours in English Springer Spaniels [11]. Another
CMT study found mutations in the cancer-associated
gene TP53 [12]. We have previously identified a consider-
able number of single nucleotide polymorphisms (SNPs) in
ten cancer-associated genes known from studies in dogs
and/or humans [13]. Some of these SNPs are likely to be as-
sociated with canine cancer, and the protein-changing SNPs
are of particular interest due to their potential as functional
disease-causing variants. In the present study, we aimed at
exploring such CMT associations to identify genes involved
in the development of mammary tumours in a case-control
population of English Springer Spaniels (ESS) and in a sec-
ond dataset of high and low risk breeds of CMT.
Results
After quality control, 165 ESS cases and 94 controls
were left for analysis (Table 1). Of the 41 SNPs that
passed quality control in the ESS case-control dataset,
nominal single SNP association was found for two SNPs in
ESR1 exon 2 (rs21960513) and intron 7–8 (ss244244344)Table 1 Datasets and samples
Dataset/Breed No. samples CMT grouping







Boxer 50 46 High risk
Cocker Spaniel 50 46 High risk
Dachshund 50 48 High risk
English Setter 50 50 High risk
Standard Poodle 50 47 High risk
Beagle 50 47 Low risk
Bernese Mountain Dog 50 49 Low risk
Collie 50 45 Low risk
Shetland Sheepdog 50 50 Low risk
a QC: Quality control.
b Subset from the study by Rivera et al. [11].
c As identified by histopathology by a veterinary pathologist at the time of the
genotyping analysis. See Methods for further description.(PRaw = 0.033 and 0.002, respectively, Table 2). Another
SNP in ESR1 (ss244244343) showed borderline nominal
significance (PRaw = 0.052). The risk alleles for the two
SNPs ss244244344 and ss244244343 are extremely com-
mon in the ESS cohort (Table 2). The ss244244344 and
rs21960513 SNPs were still significant after correcting for
multiple testing using 10,000 permutations (PPerm = 0.018
and 0.042, Table 2). Ss244244344 also remained significant
after applying Bonferroni correction. Of the classified
cases, 32 malignant and 78 benign were left after quality
control (Table 1). In the comparison of cases with malig-
nant diagnosis vs. controls, ss244244344 showed nominal
significance (PRaw = 0.016. Additional file 1: Table S3), but
the result was not significant after multiple testing cor-
rection. We found no significant differences in allele fre-
quencies between benign cases and controls or malignant
and benign cases. All association results are provided in
Additional file 1.
We identified 11 LD blocks with D’ ~ 1 and LOD ≥ 2
in the ESS case-control dataset. One LD block was iden-
tified in each of the genes BRCA2, BRIP1, CDH1,
CHEK2, EGFR and PTEN, whereas two and three blocks
were found within ESR1 and ERBB2 (HER2), respect-
ively. Only one SNP was genotyped in BRCA1 and
STK11, making LD and haplotype analysis impossible.
Nominal association was found for one and two haplo-
types in each of two ESR1 LD blocks, respectively, and
one haplotype showed borderline nominal significance
(Table 3). No haplotypes remained significant after cor-
rection for multiple testing. As the total cancer risk of
an individual is probably a result of risk alleles at mul-
tiple loci, we evaluated the combined effect of the risk
haplotypes of the two ESR1 LD blocks compared to the
protective haplotypes. A borderline Bonferroni-significant
association was found for the combined risk haplotypes
with an odds ratio of 3.3 (PBonf = 0.055) (Table 4).
In the second dataset, 237 dogs of high risk breeds,
191 dogs of low risk breeds and 43 SNPs passed quality
control and were included in the study of allele frequen-
cies (Table 1). Nineteen of the 31 SNPs with nominal
single SNP associations were significant after 107 permu-
tations, 23 after Bonferroni correction, and among them
were the three ESR1 SNPs rs21960513, ss244244343 and
ss244244344 (Table 5).
However, there were considerable inter-breed variations
in SNP allele frequencies for the high and low risk dataset
also within the high and low risk breed groups (Table 6).
Thus, the mean allele frequency of the group was often not
representative for all the breeds included. The overall dif-
ferences in allele frequency among breeds also caused gen-
eral inflation of association P-values, complicating the
interpretation. Breed permutation testing was therefore
performed to correct for the inflation. None of the SNPs
were significant after breed permutation testing (Table 5).












ESR1 INT 7-8a ss244244344 A 0.033 0.106 G 0.002 0.021 0.018 0.3
ESR1 EX 2 rs21960513 C 0.299 0.391 T 0.033 0.362 0.042 0.7
ESR1 EX 4 ss244244343 G 0.006 0.027 A 0.052 0.568 0.155 0.2
(n = 165 and n = 94, respectively, after QC).
a P-value from chi-square test in PLINK.
b Bonferroni corrected for the number of LD blocks (11).
c EMP1 value after 10,000 permutations in PLINK.
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Bonferroni significant polymorphisms, correlation be-
tween disease risk and average breed allele frequency for
each SNP was calculated. No statistically significant cor-
relations were found.
We applied the LD block criteria D’ ~ 1 and LOD ≥ 2 to
the second dataset to study if any of the blocks found in
the ESS cases and controls could be re-identified in the
high and low risk breeds. Not all blocks were present in all
breeds, but a 9kilobase block of eight SNPs in ERBB2
(ss244244354, ss244244355, ss244244357, ss244244358,
ss244244360, ss244244361, ss244244363 and ss244244364)
was re-identified for all breeds but the Beagle.
When aligned in SequencherW the canine ESR1 exons
showed a high match percentage (≥84%) to the human
exons, except for exon 1 and 8. We found no human
cancer-associated polymorphisms in close proximity to the
canine ESR1 exon 2 SNP (rs21960513). However, the ca-
nine SNP in exon 4 (ss244244343) was positioned one base
pair (bp) next to the human rs1801132 SNP (Figure 1). An-
other human ESR1 polymorphism, rs2228480, aligned to
the canine exon 8 at a position 207 bp downstream from
the canine exon 8 SNP (ss244244346) (minimum match
percentage of 84%) (Figure 1). The canine SNPs
rs21960513 and ss244244346 were synonymous, while
ss244244343 lead to an amino acid substitution from iso-







ESR1 EX 2 and ESR1 EX 4 (rs21960513 and ss244244343)
TA 0.668 0.701 0.610 0.035 0.381 0.549 1.5
CA 0.318 0.293 0.363 0.098 1.000 0.941 0.7
CG 0.014 0.006 0.027 0.052 0.572 0.741 0.2
ESR1 INT 7-8a, –b and ESR1 EX 8 (ss244244344, ss244244345 and ss244244346)
GTG 0.791 0.818 0.744 0.047 0.517 0.683 1.5
ACA 0.091 0.070 0.129 0.024 0.264 0.480 0.5
a P-value from chi-square test in Haploview.
b Corrected for the number of LD blocks available (11).
c Permutation P-value from Haploview, 10,000 permutations.region conserved across four species [13]. However,
the substitution was predicted benign and tolerant by
PolyPhen and SIFT, respectively [13,14].
Discussion
Publications about the existence, frequency and import-
ance of CMT-associated germline mutations and their role
in the tumour development are sparse. In the present sur-
vey, we studied SNPs in known cancer-associated genes
and observed significant differences in allele and haplotype
frequencies for the ESR1 gene in the ESS material. These
findings were supported by the high and low risk breed
groups and suggested an association of ESR1 alleles with
increased risk of CMTs. The ESR1 gene encodes an estro-
gen receptor which works as a ligand-activated transcrip-
tion factor in the cell. Besides its normal role in e.g. sexual
development and reproductive function, the estrogen re-
ceptor is involved in several pathological processes such as
breast cancer (as reviewed by Dahlman-Wright et al. 2006
[20]). Previous studies on human breast cancer have sug-
gested that ESR1 polymorphisms are associated with the
development of these tumours (Additional file 2). The
non-synonymous canine exon 4 SNP (ss244244343) is po-
sitioned one bp downstream compared to the position of
the human rs1801132 SNP. While rs1801132 is in human
codon 325, the canine SNP aligned to a position in human
codon 326. Both codons encode amino acids in the hor-
mone binding domain of the human estrogen receptor
(Figure 1). This domain is related to receptor dimerization,
chaperone binding and recruitment of co-regulators [21].
Studies on rs1801132 have shown an association with
breast malignancies [22,23]. Its C allele has been associated
with cancer, suggesting that it interferes with the binding
of the GATA-1 and GATA-2 transcription factors to the
estrogen receptor [21]. GATA transcription factors interact
with the activation factor 2 (AF2) region of the ligand bind-
ing domain of the human estrogen receptor [15]. There are
structural differences in the human and canine ERα pro-
teins, but the major pocket sites seem to be very similar
[24]. An association with breast cancer has also been sug-
gested for the human rs2228480 [25], which aligned in
proximity of the synonymous canine exon 8 SNP
(ss244244346). Rs2228480 is positioned near the F domain
Table 4 Combined effect of the haplotypes of the two ESR1 LD blocks in ESS cases and controls






TA-GTG (risk) 207 97 Risk TA-GTG vs. rest 1.8 (1.2 - 2.8) 0.007 0.077
Risk TA-GTG vs. protective CA-ACA 3.3 (1.4 - 7.9) 0.005 0.055
CA-ACA (protective) 9 14 Protective CA-ACA vs. rest 0.3 (0.1 - 0.8) 0.010 0.110
Other c 56 41
a Fisher-Exact test applied due to low counts of the CG haplotype (less than five in both cases and controls).
b Corrected for the number of LD blocks (11).
c For 29 cases and 18 controls, the haplotype combinations could not be fully determined due to genotyping failure of one or more of the ESR1 SNPs.
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believed to be important for the ability of estrogen receptor
to distinguish between receptor agonist and antagonist
binding [26]. Thus, the observed associations of the canine
exon 4 and exon 8 SNPs in our two independent canine
datasets are supported by similar effects of closely linked






High risk breeds Low ris
CHEK2 INT 8-9 ss244244336 G 0.269 0.0
ESR1 EX 2 rs21960513 T 0.629 0.3
ERBB2 EX 14 rs24537331 A 0.253 0.5
BRCA2 INT 18-19 ss244244323 G 0.000 0.1
ERBB2 INT 3-4 ss244244348 G 0.330 0.6
BRCA2 EX 11 rs23244160 G 0.174 0.3
CHEK2 INT 5-6 ss244244335 G 0.051 0.0
ESR1 EX 4 ss244244343 G 0.061 0.3
PTEN EX 9 ss244244369 T 0.112 0.3
BRCA2 EX 5 rs23250374 C 0.429 0
ERBB2 INT 12-13b rs24537327 A 0.485 0.2
ERBB2 EX 13b rs24537329 T 0.486 0.2
PTEN INT 7-8 ss244244368 A 0.183 0.3
BRCA2 5UTR ss244244322 T 0.343 0.5
PTEN INT 3-4 ss244244367 G 0.191 0.3
STK11 INT 1-2 rs22928814 T 0.241 0.3
BRIP1 EX 19b ss244244329 T 0.538 0.3
ERBB2 INT 8-9 ss244244349 G 0.089 0.0
ESR1 INT 7-8a ss244244344 A 0.124 0.2
BRIP1 INT 8-9a ss244244325 G 0.135 0.0
ERBB2 INT 1-2 ss244244347 T 0.021 0.0
BRIP1 INT 15-16 ss244244327 T 0.131 0.0
ERBB2 EX13a rs24616607 G 0.044 0.0
(n = 237 and n = 191, respectively, after QC).
a P-value from chi-square test.
b Corrected for the number of across-breed LD blocks (9).
c EMP1 value after 107 permutations.
d EMP1 value after 10,000 breed permutations.
e OR could not be calculated as the minor allele was absent in either cases or contrinteresting candidate gene for mammary tumours in dogs
as well. Given the prior evidence that ESR1 plays a role in
human breast cancer etiology, it seems probable that the
described loci of the present study might be correlated
with a causal variant affecting ESR1 function.
Correction for multiple testing is necessary to adjust









40 T 8.8 8.6E-19 7.8E-18 <1.0E-07 0.076
05 C 3.9 5.0E-21 4.5E-20 <1.0E-07 0.107
11 G 0.3 8.4E-15 7.6E-14 <1.0E-07 0.110
33 A _ e 1.8E-16 1.6E-15 <1.0E-07 0.110
81 A 0.2 2.4E-24 2.2E-23 <1.0E-07 0.112
46 T 0.4 8.4E-09 7.6E-08 4.2E-05 0.151
00 A _ e 9.6E-06 8.6E-05 0.005 0.182
94 A 0.1 9.8E-33 8.8E-32 <1.0E-07 0.204
46 C 0.3 1.3E-16 1.2E-15 <1.0E-07 0.209
.23 T 2.5 1.1E-09 1.0E-08 1.0E-05 0.321
83 G 2.4 2.2E-09 1.9E-08 2.0E-05 0.362
85 C 2.4 2.4E-09 2.2E-08 2.1E-05 0.368
56 G 0.5 8.0E-09 7.2E-08 4.0E-05 0.385
06 C 0.5 2.7E-06 2.4E-05 0.002 0.407
46 A 0.6 2.8E-07 2.5E-06 5.0E-04 0.416
62 C 0.6 1.1E-04 1.0E-03 0.031 0.476
86 T 1.9 9.9E-06 8.9E-05 0.006 0.521
27 A 3.2 0.001 5.8E-03 0.101 0.566
23 G 0.5 2.3E-04 2.2E-03 0.051 0.708
11 A 14.5 3.2E-11 2.9E-10 <1.0E-07 0.817
00 C _ e 0.005 0.045 0.340 0.845
11 A 14.0 8.0E-11 7.2E-10 <1.0E-07 0.874
05 C 8.5 0.001 5.2E-03 0.095 0.983
ols.
Table 6 Breed-wise average allele frequencies in the high and low risk breed dataset













BRCA2 5UTR T 0.138 0.589 0.682 0.177 0.167 0.244 0.904 0.524 0.330
BRCA2 EX 5 C 0.130 0.848 0.292 0.160 0.720 0.141 0.684 0.055 0.011
BRCA2 EX 11 G 0.202 0.141 0.417 0.020 0.100 0.160 0.245 0.556 0.436
BRCA2 INT 18-19 G 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.463 0.117
BRIP1 INT 8-9a G 0.660 0.000 0.021 0.000 0.010 0.021 0.020 0.000 0.000
BRIP1 INT 15-16 T 0.652 0.000 0.021 0.000 0.010 0.021 0.020 0.000 0.000
BRIP1 EX 19b T 0.872 0.705 0.187 0.120 0.837 0.489 0.204 0.033 0.809
CHEK2 INT 5-6 G 0.033 0.159 0.073 0.000 0.000 0.000 0.000 0.000 0.000
CHEK2 INT 8-9 G 0.670 0.120 0.271 0.270 0.050 0.064 0.073 0.000 0.021
ESR1 EX 2 T 0.967 0.772 0.729 0.410 0.310 0.670 0.102 0.213 0.234
ESR1 EX 4 G 0.011 0.043 0.000 0.000 0.240 0.053 0.000 0.791 0.766
ESR1 INT 7-8a A 0.000 0.083 0.044 0.600 0.000 0.000 0.942 0.000 0.000
ERBB2 INT1-2 T 0.106 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
ERBB2 INT 3-4 G 0.033 0.326 0.365 0.720 0.173 0.223 0.918 0.637 0.936
ERBB2 INT 8-9 G 0.043 0.318 0.052 0.020 0.000 0.109 0.000 0.000 0.000
ERBB2 INT 12-13b A 0.915 0.533 0.542 0.240 0.230 0.798 0.071 0.225 0.043
ERBB2 EX 13a G 0.223 0.000 0.000 0.000 0.000 0.000 0.020 0.000 0.000
ERBB2 EX 13b T 0.926 0.533 0.531 0.240 0.230 0.798 0.071 0.233 0.043
ERBB2 EX 14 A 0.021 0.250 0.260 0.460 0.260 0.170 0.561 0.451 0.870
PTEN INT 3-4 G 0.021 0.413 0.031 0.450 0.040 0.128 0.000 0.538 0.734
PTEN INT 7-8 A 0.000 0.076 0.000 0.470 0.340 0.128 0.010 0.544 0.766
PTEN EX 9 T 0.000 0.076 0.000 0.450 0.020 0.128 0.000 0.538 0.734
STK11 INT 1-2 T 0.394 0.348 0.156 0.010 0.310 0.213 0.745 0.467 0.011
Figure 1 Schematic illustration of ESR1 alignments relative to the human ESR1 gene sequence. The human ESR1 gene sequence (grey)
and exons (blue) with aligned canine ESR1 exons (green) and human and canine polymorphisms (purple and orange triangles, respectively). The
exon numbers are in white letters. Bars above the human exon sequences are indicating the location of the ligand binding domain (LBD, dark
brown), F domain (F, red bar), activation factor 2α domain (AF2α, light brown bar) and activation factor 2 domain (AF2, black bars). GATA
interacts with the AF2 domain [15-19].
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SNPs within a gene are very closely linked and not inde-
pendent observations. Correcting for the number of
SNPs would therefore be too conservative. Moreover,
this study comprises a selection of biologically important
and previously cancer-associated genes where it is likely
to find an association, rather than a random set of genes.
To assure an appropriate correction for multiple testing
of the single SNP and haplotype P-values, we therefore
used the number of LD blocks. The fact that only one
SNP in ESR1 was significant in the ESS material after
Bonferroni correction was somewhat surprising. Pos-
sibly, the rest of the SNPs we assessed are not directly
causative or in high LD with such variants, creating false
negative gene association results. Further, a substantial
number of sub-classifications of CMTs exists [27], po-
tentially with different germline mutations contributing
to the development of different tumour subtypes and
grades of malignancy. Such heterogeneity might compli-
cate the detection of truly cancer-associated mutations.
Thus, our study of the ESS dataset might have insuffi-
cient power to prove SNP associations to CMT. Still, it
has been indicated that about 100 cases and 100 controls
should suffice to find loci with strong effects (fivefold)
even for complex traits such as cancer [28]. As the one
Bonferroni significant ESR1 SNP (ss244244344) is in-
tronic, and we have tested only a limited set of SNPs,
this SNP is more likely in LD with a functional mutation
than being causative itself. It might also be a false posi-
tive. Thus, more studies on the ESR1 gene are required
to establish its role in CMT development.
The considerable breed variations in allele frequencies
for the high and low risk dataset might be expected due
to between-breed genetic heterogeneity for risk alleles at
different risk loci. Yet, the differences are interesting as
it appears to be a significant breed-specific accumulation
of certain coding variants also in genes that are vital for
normal cell function. However, the large allele frequency
differences between breeds within the same risk group
complicated the interpretation of the results. There is
potentially a genetic heterogeneity between breeds as to
predominant CMT types and associated risk genes/al-
leles. If the candidate genes in this study are associated
with cancer risk in the selected breeds, the variation in
allele frequencies indicates that the associated genes/al-
leles differ between breeds. Another possibility is that
cancer-driving mutations are in the regulatory parts of
the genes, and the coding SNPs in the present study
can be considered markers for functionally active regu-
latory sites. During breed differentiation there may have
been recombinations between regulatory sites and cod-
ing parts resulting in different coding SNPs being
linked to regulatory variation in different breeds. Conse-
quently, even if a gene has an important role in cancerdevelopment, the associated coding SNP allele/haplotype
might vary between breeds. Another challenge is the
documentation of high and low risk breeds. As a result of
e.g. ancestral patterns of geographical establishment,
fluctuations in a dog breed’s popularity and extensive use
of popular sires within a country, the genetic compos-
ition of a dog breed can change over time and between
different geographical locations. Thus, breed predispos-
ition of CMT might vary from subpopulation to subpop-
ulation. We based the selection of high and low risk
breeds in this study on previous publications, but not all
of them were Norwegian, and some were up to twenty
years old. This could possibly be a source of sample error
in our study. Moreover, the dogs from the high and low
risk breeds in our study are randomly selected without
knowledge about the CMT phenotype. They would be a
mixture of individuals with high and low risk corre-
sponding to the population frequency of CMT. The fre-
quency and effect of CMT-associated risk alleles would
need to be relatively strong to be detected in such a ma-
terial. It might be that our study is underpowered in that
respect. However, we have documented large breed varia-
tions in allele frequencies of the coding SNPs in import-
ant cancer genes, and there are probably similar
differences in the frequency of functionally active haplo-
types between dog populations.
Conclusions
Cancer is a very complex disease. As in human breast
malignancies, it is likely that the development of CMTs
is influenced by several genes. The identified association
of ESR1 to CMT in the present survey supports the
power of the canine model for human breast cancer and
the fact that combined studies within and between
breeds can add power to the detection of risk alleles also
for complex traits. However, the increased risk of CMTs
in ESS and other high risk breeds might be due to other
SNPs and/or genes than those selected in the present
study. There is also a chance that predisposing CMT
variants are undetected in our study due to limited
power. Nevertheless, this is to our knowledge the first
reported association of ESR1 polymorphisms to CMT
and supports ESR1 as a candidate gene for canine cancer
that should be further studied.
Methods
Samples
Two separate datasets were included in this study. The
first consisted of blood DNA from English Springer
Spaniel CMT cases and controls [11] (Table 1). These
were privately owned female dogs registered in the
Swedish Kennel Club. Approximately half of the dogs
were confirmed unrelated at the parental level, while the
rest could be as closely related as siblings. A subset of










BRCA1 17 9 1 23.306
BRCA2 13 25 5 10.782-10.732
BRIP1 17 9 5 38.191-38.304
CDH1 16 5 5 83.792-83.771
CHEK2 22 26 3 25.104-25.086
EGFR 7 18 5 8.982-9.027
ERBB2 (HER2) 17 9 18 26.106-26.088
ESR1 6 1 5 45.129-45.409
PTEN 10 26 4 40.921-40.978
STK11 19 20 1 60.709
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nign (n = 83) CMTs by histopathology by a veterinary
pathologist at the time of the genotyping analysis. The
rest of the cases were selected based on a veterinary
clinical examination confirming the presence of single or
multiple nodules within the mammary glands, but they
had not (yet) had their mammary tumours surgically re-
moved or histopathologically evaluated. The control
dogs were older than eight years with confirmed absence
of CMT after palpation of the mammary glands by a vet-
erinarian. However, some of the samples from the ma-
terial by Rivera et al. were not available for the present
study. The same ESS cohort has been genotyped in a
parallel study using Illumina 170 K canine HD SNP
array, and multidimensional scaling plots were used to
evaluate population stratification (data not shown). In
this analysis, an outlier group of 29 dogs was identified.
These dogs were consequently removed from further
analysis in the present study.
The second dataset consisted of EDTA blood samples
from the Canine Biobank at the Norwegian School of
Veterinary Science (NSVS). In total, this dataset com-
prised samples from 450 individuals of nine dog breeds
(Table 1). The selected breeds were known to be at ei-
ther high or low risk of developing CMTs according to
previous studies. However, the CMT status of the indi-
vidual dogs from the Canine Biobank was unknown. But
according to the higher genetic risk for some of the
breeds, an increased allele frequency of associated risk
alleles would be expected. Representing breeds at high
risk, the Boxer, Cocker Spaniel, Dachshund, English
Setter and Standard Poodle were selected. Assumed
low risk breeds included in the study were the Beagle,
Bernese Mountain Dog, Collie and Shetland Sheepdog
[3-8]. Genomic DNA was extracted from the EDTA blood
samples using E.Z.N.A Blood Kit according to the manu-
facturer’s protocol (Omega W, VWR International, West
Chester, Pennsylvania, USA). The DNA was analysed for
quality and quantity using NanoDrop (Thermo Fisher Sci-
entific, Wilmington, Pennsylvania, USA).Single nucleotide polymorphism selection and genotyping
All samples were genotyped for 52 previously de-
scribed canine SNPs [13] (Additional file 3). These
SNPs were located in ten genes previously reported
to be cancer-associated in humans; BRCA1, BRCA2,
BRIP1, CDH1, CHEK2, EGFR, ERBB2 (HER2), ESR1,
PTEN and STK11 (Table 7). Twenty of the SNPs
were found in coding regions, including 11 synonym-
ous and 9 non-synonymous SNPs. The SNPs were
distributed into two pools and genotyped using the
Sequenom iPLEX Gold Mass ARRAYW according to
the manufacturer’s protocol (SequenomW, San Diego,California, USA). The genotyping was performed at
Broad Institute, Cambridge, Massachusetts.
Single SNP and haplotype association analysis
Single SNP and haplotype analysis were performed sep-
arately for the two different study datasets; the ESS cases
were compared to the controls, and the high risk breeds
from the Canine Biobank were all compared to the low
risk breeds. Single SNP association analysis was also
performed for the subset of ESS cases with benign tu-
mours vs. controls, malignant tumours vs. controls and
benign vs. malignant tumours. Only samples and SNPs
with a genotyping success rate of ≥75% and SNPs with a
minor allele frequency (MAF) ≥1% were included in the
single SNP and haplotype association analysis. The
PLINK software [29,30] was used for analysing allele fre-
quencies, single χ2 SNP association and SNP odds ratios.
Haploview [31,32] was used to identify LD blocks with a
D’ ~ 1 and LOD ≥ 2 for each dataset and to generate
haplotypes and haplotype association statistics. Odds ra-
tios for haplotypes at each specific locus were estimated
using calculators at VassarStats [33]. The nominal (raw)
χ2 P-values from the single SNP and haplotype analysis
were Bonferroni corrected using the number of LD
blocks to adjust for the problem of multiple comparisons
that arises from evaluating several SNPs or haplotypes.
Multiple testing correction using 10,000 permutations
for the ESS dataset and 107 permutations for the high
and low risk breed dataset was also performed. Further,
we did permutation testing by permuting the high/low
risk labels simultaneously for all dogs in each breed in
combination with PLINK analysis of association, using
10,000 permutations. A P-value of less than 0.05 after
correction for multiple testing was reckoned statistically
significant.
Considering each individual breed as the study unit
rather than the individual dog, we performed pairwise
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using JMP 8 (SAS Institute Inc., North Carolina, USA).
The correlation between the disease risk (high or low) and
average allele frequency for each breed for each SNP was
estimated, regarding a P-value of less than 0.05 statistically
significant. Bonferroni correction was performed using the
number of LD blocks across breeds (9).
Known human breast cancer-associated ESR1 poly-
morphisms (Additional file 2) were compared to the
canine SNPs in this study by alignment using the
Sequencher software (Gene Codes Corporation, Ann
Arbor, MI, USA). The full genomic human ESR1
gene sequence [ENST00000206249] was aligned to the
canine [ENSCAFT00000000680, (CanFam2.0)] [16] and
human exon sequences and polymorphisms with
flanking sequence.
Additional files
Additional file 1: All results from ESS single SNP and haplotype
association analysis.
Additional file 2: Cancer-associated human ESR1 polymorphisms
that were compared to the canine SNPs.
Additional file 3: Genotyped single nucleotide polymorphisms,
genome position, reference ID and alleles.
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